Yi-Ping Huang | Pharmaceutical Science | Women Researcher Award

Posted on by ScienceFather

Assoc. Prof. Dr. Yi-Ping Huang | Pharmaceutical Science | Women Researcher Award

Associate Professor from Department of Physiology, China Medical University, Taiwan

Yi-Ping Huang is an accomplished Associate Professor in the Department of Physiology at China Medical University, with over 32 years of experience in both teaching and research. His primary focus is on cancer treatment, specifically investigating the therapeutic effects of natural and synthetic compounds on cancer cells. Over the years, Huang has significantly contributed to the field, publishing numerous peer-reviewed articles and advancing the understanding of cancer treatment mechanisms, particularly apoptosis, DNA damage, and anti-metastasis pathways. His expertise extends to drug synergy, especially in combination with chemotherapy. He has also been involved in teaching innovations in physiology, emphasizing student engagement and educational research. Huang’s extensive research output and leadership in the field have made him a well-respected figure in the scientific community, as reflected in his numerous research projects and academic publications.

Professional Profile

Education

Yi-Ping Huang completed his undergraduate studies in Physiology at Yang-Ming University, laying the foundation for his extensive career in research and academia. His academic journey provided a strong base for his research into cancer treatment and physiological mechanisms. This solid educational background enabled Huang to develop expertise in a range of specialized topics, particularly in the therapeutic effects of natural compounds. Over the years, his continuous learning and commitment to his field have propelled his success, making him an established academic in the study of cancer therapy and physiology.

Professional Experience

Yi-Ping Huang has a long and distinguished career in both academia and research. As an Associate Professor at China Medical University, he has been instrumental in educating students and conducting cutting-edge research on cancer therapy. With over three decades of experience, Huang has led numerous research projects focusing on natural and synthetic compounds in cancer treatment. His role also includes teaching and mentoring students, guiding them in the latest scientific advancements. Huang’s professional experience is marked by extensive publications in high-impact journals, further showcasing his contributions to the scientific community and his leadership in advancing cancer research.

Research Interests

Yi-Ping Huang’s primary research interests revolve around the use of natural and synthetic compounds in cancer therapy. His work explores the mechanisms through which these compounds induce apoptosis, DNA damage, and inhibit metastasis in cancer cells. Huang is particularly focused on understanding how these compounds can synergize with chemotherapy drugs to overcome resistance and improve treatment outcomes. His ongoing research also investigates the therapeutic effects of compounds such as Demethoxycurcumin (DMC), Phenethyl Isothiocyanate (PEITC), and PW06 in various cancer types, including glioblastoma and colon cancer. These areas of interest align with his goal of advancing cancer therapy through the identification and development of novel therapeutic agents.

Research Skills

Yi-Ping Huang’s research skills are extensive and diverse, ranging from molecular biology techniques to cancer therapy research. He possesses a deep understanding of cancer cell biology, particularly in apoptosis, DNA repair, and metastasis inhibition. Huang has demonstrated proficiency in the use of various experimental models to study the effects of natural and synthetic compounds on cancer cells, including in vitro and in vivo models. His expertise extends to studying drug interactions and mechanisms of drug resistance, especially in relation to chemotherapy. Huang’s interdisciplinary approach to research, combining pharmacology, molecular biology, and cancer therapy, has led to groundbreaking studies that have contributed significantly to the field.

Awards and Honors

Throughout his illustrious career, Yi-Ping Huang has received numerous awards and honors that recognize his contributions to the scientific community. His groundbreaking research in cancer therapy, particularly in the use of natural and synthetic compounds, has earned him accolades from academic institutions and scientific organizations. Huang’s work on compounds such as Demethoxycurcumin and Phenethyl Isothiocyanate has been widely recognized in the field of oncology research. His consistent contributions to cancer treatment research and his leadership in academia have earned him recognition as a leading expert in his field, enhancing his reputation as an influential figure in cancer research.

Conclusion

Yi-Ping Huang’s career has been defined by significant contributions to cancer research, particularly in the development and understanding of natural and synthetic compounds as therapeutic agents. His research focuses on the molecular mechanisms of apoptosis, DNA damage, and anti-metastasis, offering potential for groundbreaking advancements in cancer treatment. With over three decades of experience, Huang’s work continues to influence both basic and clinical cancer research. His leadership in academia, coupled with his innovative research, positions him as a respected figure in the scientific community. As he continues to push the boundaries of cancer therapy, his contributions are likely to have a lasting impact on the field.

Publication Top Notes

M084 causes cell cycle arrest and inhibits voltage-gated Na⁺ and K⁺ channels in neuronal N2A cells
Authors: Iat Lon Leong, Chinmin Chuang, Chenghsun Wu, Yukman Leung, Yiping Huang
Year: 2025

2. MCU-i4, a mitochondrial Ca²⁺ uniporter modulator, induces breast cancer BT474 cell death by enhancing glycolysis, ATP production and reactive oxygen species (ROS) burst
Authors: Edmund Cheung So, Louis Wing Cheong Chow, Chinmin Chuang, Yukman Leung, Yiping Huang
Year: 2025

3. Physalin A induces apoptosis through conjugating with Fas-FADD cell death receptor in human oral squamous carcinoma cells and suppresses HSC-3 cell xenograft tumors in NOD/SCID mice
Authors: Fu Shin Chueh, Shengyao Hsu, Kuangchi Lai, Yiping Huang, Wen Tsong Hsieh
Year: 2025

4. PEITC Induces DNA Damage and Inhibits DNA Repair-Associated Proteins in Human Retinoblastoma Cells In Vitro
Authors: Shengyao Hsu, Yiping Huang, Techun Hsia, Fu Shin Chueh, Chaolin Kuo
Year: 2024

5. Armillaria mellea Mycelia Alleviate PM2.5-Induced Pulmonary Inflammation in Murine Models
Authors: Yiping Huang, Yutsen Huang, Huiyu Wu, Chinchu Chen, Chih Ho Lai
Year: 2024

6. RAGE participates in the intracellular transport of Campylobacter jejuni cytolethal distending toxin
Authors: Yufang Chang, Yiping Huang, Chiahuei Chou, Chenghsun Chiu, Chih Ho Lai
Year: 2024
Citations: 2

7. PW06 suppresses cancer cell metastasis in human pancreatic carcinoma MIA PaCa-2 cells via the inhibitions of p-Akt/mTOR/NF-κB and MMP2/MMP9 signaling pathways in vitro
Authors: Yiping Huang, Chunan Yeh, Yishih Ma, Jin Cherng Lien, Wen Tsong Hsieh
Year: 2024
Citations: 2

Na Zhang | Pharmaceutical Science | Best Researcher Award

Posted on by ScienceFather

Prof. Na Zhang | Pharmaceutical Science | Best Researcher Award

Shandong university, China.

Dr. Na Zhang is a distinguished professor at the Institute of Pharmaceutics, Shandong University, China. She earned her Ph.D. in Pharmaceutics from China Pharmaceutical University in July 2004, following her Master’s and Bachelor’s degrees in Pharmacy from Shandong Medical University. Over her extensive career, Dr. Zhang has made significant contributions to the field of pharmaceutics, focusing on innovative drug delivery systems and cancer therapies. With over two decades of academic and research experience, she has established herself as a leader in her field, exemplified by her role as Associate Dean of the School of Pharmaceutical Science. Dr. Zhang’s research has garnered international recognition through numerous publications in high-impact journals, collaborative projects, and successful funding grants. She is dedicated to advancing pharmaceutical education while actively engaging in cutting-edge research that addresses critical healthcare challenges.

Professional Profile

Education

Dr. Na Zhang completed her Ph.D. in Pharmaceutics at the School of Pharmacy, China Pharmaceutical University, in July 2004. Prior to that, she obtained her Master’s degree in Pharmacy in July 1995 from Shandong Medical University, and her Bachelor’s degree in Pharmacy from the same institution in July 1992. Her educational journey has laid a solid foundation for her expertise in pharmaceutics, equipping her with the knowledge and skills to excel in both research and academic settings. Throughout her studies, Dr. Zhang has consistently demonstrated a commitment to academic excellence and innovation, which is evident in her subsequent professional achievements. Her comprehensive educational background enables her to contribute significantly to the fields of drug delivery systems and cancer immunotherapy, fostering the development of advanced pharmaceutical solutions that address pressing health issues.

Professional Experience

Dr. Na Zhang has a robust professional background spanning over two decades in academia and research. Since January 2013, she has served as a professor and Associate Dean at the School of Pharmaceutical Science, Shandong University. Prior to this, she held various positions, including Associate Professor and lecturer at Shandong University and a postdoctoral fellowship at the University of Kansas. Dr. Zhang’s career trajectory illustrates her dedication to the advancement of pharmaceutical sciences through teaching, research, and leadership. Her roles have involved mentoring students and researchers, developing curricula, and contributing to institutional governance. Dr. Zhang’s extensive experience in academia enables her to bridge the gap between scientific research and education, ensuring that her students are well-prepared for future challenges in the pharmaceutical industry.

Research Interests

Dr. Na Zhang’s research interests encompass a wide range of areas within pharmaceutics, particularly focusing on innovative drug delivery systems. She specializes in nano-drug delivery systems, exploring stimuli-responsive carriers for targeted therapy, and cancer immunotherapy. Her work on small molecule-based nanodrugs aims to enhance the efficacy and safety of cancer treatments, addressing critical challenges in current therapeutic approaches. Additionally, she engages in pre-clinical biopharmaceutical evaluation to assess the pharmacokinetics and dynamics of her developed formulations. By combining her expertise in nanotechnology and pharmaceutical sciences, Dr. Zhang seeks to contribute significantly to the field, improving treatment outcomes for patients with cancer and other complex diseases.

Research Skills

Dr. Na Zhang possesses a diverse array of research skills that enhance her effectiveness as a scientist and educator. Her expertise includes the design and development of nano-drug delivery systems, with a particular focus on creating stimuli-responsive carriers. She is proficient in pre-clinical biopharmaceutical evaluation, which involves assessing the pharmacological and therapeutic properties of new drug formulations. Additionally, Dr. Zhang has extensive experience in experimental design, data analysis, and scientific writing, which are essential for conducting high-quality research and publishing in reputable journals. Her collaborative approach fosters interdisciplinary partnerships, enhancing her research’s impact and relevance. Furthermore, her leadership in academic settings enables her to mentor aspiring researchers, sharing her knowledge and skills to cultivate the next generation of pharmaceutical scientists.

Awards and Honors

Dr. Na Zhang’s outstanding contributions to pharmaceutical sciences have earned her numerous awards and honors throughout her career. She has been recognized for her innovative research in nano-drug delivery and cancer immunotherapy, reflecting her commitment to advancing healthcare solutions. Her research has garnered prestigious funding from national bodies, highlighting the significance of her work in the field. Furthermore, Dr. Zhang has received accolades for her excellence in teaching and mentoring, demonstrating her dedication to fostering academic growth among her students. As a published author in high-impact journals, she has received recognition from peers and the broader scientific community for her contributions to advancing pharmaceutical knowledge. Her achievements underscore her influence as a researcher and educator in the pharmaceutical sciences.

Conclusion:

Dr. Na Zhang stands out as an exemplary candidate for the Best Researcher Award due to her significant contributions to pharmaceutical sciences, particularly in nano-drug delivery and cancer immunotherapy. Her impressive publication record, successful acquisition of research funding, and commitment to education reflect her dedication and impact in the field. By addressing the areas for improvement, Dr. Zhang can further enhance her influence and leadership within the global research community. Thus, she is highly deserving of this recognition.

Publications Top Notes

  1. Glypican-3-targeted macrophages delivering drug-loaded exosomes offer efficient cytotherapy in mouse models of solid tumours
    • Authors: Liu, J., Zhao, H., Gao, T., Zhang, N., Liu, Y.
    • Year: 2024
  2. Self-delivery photothermal-boosted-nanobike multi-overcoming immune escape by photothermal/chemical/immune synergistic therapy against HCC
    • Authors: Yang, H., Mu, W., Yuan, S., Liu, Y., Zhang, N.
    • Year: 2024
  3. Delivery Strategy to Enhance the Therapeutic Efficacy of Liver Fibrosis via Nanoparticle Drug Delivery Systems
    • Authors: Liu, J., Liu, J., Mu, W., Liu, Y., Zhang, N.
    • Year: 2024
    • Citations: 1
  4. In Situ Hydrogel Modulates cDC1-Based Antigen Presentation and Cancer Stemness to Enhance Cancer Vaccine Efficiency
    • Authors: Gao, T., Yuan, S., Liang, S., Zhang, N., Liu, Y.
    • Year: 2024
  5. Nano-Regulator Inhibits Tumor Immune Escape via the “Two-Way Regulation” Epigenetic Therapy Strategy
    • Authors: Liang, S., Liu, M., Mu, W., Jiang, D., Zhang, N.
    • Year: 2024
    • Citations: 3
  6. Cell Membrane Biomimetic Nano-Delivery Systems for Cancer Therapy
    • Authors: Xia, Z., Mu, W., Yuan, S., Liu, Y., Zhang, N.
    • Year: 2023
    • Citations: 2
  7. Application of Nano-Delivery Systems in Lymph Nodes for Tumor Immunotherapy
    • Authors: Xia, Y., Fu, S., Ma, Q., Liu, Y., Zhang, N.
    • Year: 2023
    • Citations: 30
  8. Temperature sensitive liposome based cancer nanomedicine enables tumour lymph node immune microenvironment remodelling
    • Authors: Fu, S., Chang, L., Liu, S., Liu, Y., Zhang, N.
    • Year: 2023
    • Citations: 32
  9. Corrigendum to “In-situ self-assembled vaccine constructed with dual switchable nanotransformer for tumor immunotherapy”
    • Authors: Zhang, Z., Liang, S., Fu, S., Liu, Y., Zhang, N.
    • Year: 2023
  10. Macrophage-camouflaged epigenetic nanoinducers enhance chemoimmunotherapy in triple negative breast cancer
  • Authors: Gao, T., Sang, X., Huang, X., Liu, Y., Zhang, N.
  • Year: 2023
  • Citations: 3